Hamilelikte naproxen kullanmaktan kaçınmalı mıyım? | VeriMom
Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
ECHA regulatory hazard statements
- •H361
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- naproxen hamilelikte güvenli mi?
- Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
- naproxen emzirirken güvenli mi?
- Naproxen is excreted into breast milk in low amounts but has a long half‑life and case reports of infant effects; professional guidance (LactMed, NHS Specialist Pharmacy Service, MotherToBaby) recommends caution and short‑term use if needed and consideration of alternative NSAIDs with shorter half‑lives. Mechanism is passive transfer into milk consistent with systemic exposure; expected exposure from topical cosmetic use is low but measurable.
- naproxen bebek cildi için güvenli mi?
- No infant‑specific dermal teratogenicity data were found; systemic hazard stems from naproxen’s known reproductive effects. For baby (0–3 yr) skin, exposure scoring is increased by +1 due to immature barrier and higher surface‑area‑to‑weight, so exposure is moderate if a naproxen‑containing topical product were used repeatedly. There is no evidence to raise hazard or mechanism above the adult systemic evidence without infant‑specific studies.
- VeriMom naproxen nasıl puanlıyor?
- VeriMom naproxen'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 20/100 (yüksek risk) olarak puanlar.
- Hamilelikte naproxen yerine neler kullanılabilir?
- Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.
Her etiketi 2 saniyede kontrol et
VeriMom'u ücretsiz indirin — herhangi bir ürünü tarayın ve hamilelik güvenlik puanını anında görün.
Tıbbi Sorumluluk Reddi
Bu bilgiler yalnızca eğitim amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Güvenlik puanları kamuya açık verilere dayanmaktadır ve tüm riskleri yansıtmayabilir. Hamilelik veya emzirme döneminde herhangi bir ürünü kullanmadan önce her zaman sağlık uzmanınıza danışın.